Commonwealth Bank's Fiscal Year Profit Falls, Raises Dividend
By Alice Uribe
SYDNEY--Commonwealth Bank of Australia posted a 6% fall in annual net profit, with growth in its core businesses offset by lower lending and deposit margins.
CBA, Australia's biggest bank by market value and the country's largest mortgage lender, said its net profit fell to 9.39 billion Australian dollars (US$6.23 billion) in the 12 months through June. Full-year revenue was down 2% on year to A$26.92 billion.
Consensus forecasts compiled by FactSet projected CBA's full-year profit at A$9.50 billion.
Cash earnings--the measure followed by analysts that strips out items including hedging and losses or gains on acquisitions and asset sales--fell by 2% to A$9.84 billion from the previous year.
Directors of the company declared a final dividend of A$2.50 a share, up from A$2.40 a share last year.
The bank's closely watched Common Equity Tier 1 capital ratio, a key measure of a bank's ability to withstand financial shocks, was 12.3% in fiscal 2024, up 10 basis points compared to the previous year.
Write to Alice Uribe at alice.uribe@wsj.com
(END) Dow Jones Newswires
August 13, 2024 18:04 ET (22:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks